HomeAI · summaries
Storia in 4 fonti
Compounders maintain a firm grip on the GLP-1 market
Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients taking are still taking cheaper weight-loss alternatives.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
hrdive.com
Employers push health savings plans, nutritional counseling to avoid GLP-1 coverage for weight loss
Cost remains a major factor for employers as the popular drug for weight loss represented 11.4% of annual claims for corporations in 2025.
- ·
washingtonexaminer.com
The deceptive advertisements masking drug dangers
Compounded GLP-1 weight-loss ads are flooding social media without FDA oversight or safety warnings — putting patients, especially teenagers, at serious risk.
